The mechanism whereby agonist occupancy of muscarinic cholinergic receptors elicits an increased tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin has been examined. Addition of oxotremorine-M to SH-SY5Y neuroblastoma cells resulted in rapid increases in the phosphorylation of FAK (t 112 = 2 mm) and paxillin that were independent of integrin-extracellular matrix interactions, cell attachment, and the production of phosphoinositide-derived second messengers. In contrast, the increased tyrosine phosphorylations of FAK and paxillin were inhibited by inclusion of either cytochalasin D or mevastatin, agents that disrupt the cytoskeleton. Furthermore, phosphorylation of FAK and paxillin could be prevented by addition of either wortmannin or LY-294002, under conditions in which the synthesis of phosphatidylinositol 4-phosphate was markedly attenuated. These results indicate that muscarinic receptor-mediated increases in the tyrosine phosphorylation of FAK and paxillin in SH-SY5Y neuroblastoma cells depend on both the maintenance of an actin cytoskeleton and the ability of these cells to synthesize phosphoinositides.
Focal adhesion kinase (FAK) is a 125-kDa cytoplasmic protein tyrosine kinase originally identified in v-src-transformed chicken embryo fibroblasts . Integrin-mediated attachment of fibroblasts to extracellular matrix (ECM) proteins induces the tyrosine phosphorylation of FAK, increased kinase activity, and localization to focal adhesions (Burridge et al., 1992; Guan and Shalloway, 1992; Hanks et al., 1992; Kornberg et al., 1992) . Several putative downstream substrates for FAK have been identified, one of which is the cytoskeletal protein paxillin (Bellis et al., 1995; Schaller and Parsons, 1995) . Thus, FAK has been implicated as a potential regulator of integrin-mediated signal transduction and cytoskeletal assembly at sites of developing focal adhesions. Recently, FAK has been identified in neural tissue both in vitro (Zhang et al., 1994; Derkinderen et al., 1996) and in vivo (Grant et al., 1995) . Furthermore, both FAK and paxillin have been implicated in a signal transduction pathway linked to neurite outgrowth (Bianchi et al., 1995; Maroney et al., 1995; Leventhal and Feldman, 1996; Leventhal et al., 1997) .
In addition to integrin activation, the tyrosine phosphorylation of FAK is enhanced in fibroblasts in response to multiple stimuli, including transformation by retroviral oncogenes (Guan and Shalloway, 1992) , growth factors for receptor tyrosine kinases (Rankin et al., 1996) , bioactive lipids (Seufferlein and Rozengurt, 1994a,b) , and phorbol esters (Sinnett-Smith et al., 1993) . Furthermore, agonist occupancy of receptors that couple to phosphoinositide hydrolysis has also been demonstrated to elicit an increase in the tyrosine phosphorylation of FAK, although the mechanism whereby this occurs has yet to be defined (Sinnett-mAChR AND FAK PHOSPHORYLATION 941 Smith et al., 1993; Leeb-Lundberg et al., 1994; Rankin et al., 1994) .
Recently it was reported that activation of muscarinic cholinergic receptors (mAChRs) present on SH-SY5Y neuroblastoma cells resulted in morphological changes characteristic of neurite outgrowth (Rösner et al., 1995) . Given that (a) mAChRs on these cells are known to couple to phosphoinositide hydrolysis Slowiejko et al., 1996) and (b) the presence of both FAK and paxillin has been documented in SH-SY5Y cells (Leventhal and Feldman, 1996; Leventhal et al., 1997) , the observations of Rosner et al. (1995) prompted us to determine whether the activation of mAChRs in SH-SY5Y cells resulted in an increased tyrosine phosphorylation of FAK and, if so, the mechanism by which this occurs.
The results indicate that, on agonist occupancy of mAChRs in SH-SY5Y cells, there is a rapid increase in the tyrosine phosphorylation of FAK and paxillin. This appears to occur independently of the production of phosphoinositide-derived second messengers but is absolutely dependent on the presence of an intact actin cytoskeleton. Agonist-stimulated tyrosine phosphorylation of both FAK and paxillin was also blocked by pretreatment of the cells with either wortmannin or LY-294002 [2-(4-morpholinyl ) -8-phenyl-4H-1-benzopyran-4-one 1~under conditions in which the synthesis of phosphatidylinositol (PT) 4-phosphate [P1(4) F] was markedly attenuated. The data suggest that the maintenance of an actin microfilament network and the continuous ability of these cells to synthesize phosphoinositides are prerequisites for the tyrosine phosphorylation of FAK and paxillin that occurs in response to mAChR activation. A preliminary account of part of this study has previously been reported (Linseman et al., 1997) .
MATERIALS AND METHODS

Materials
Cytochalasin D, thapsigargin, phorbol 12-myristate 13-acetate (PMA), Ro 31-8220, ML-7, arachidonyl trifluoromethyl ketone (AACOCF 3), quinacrine, 1-oleoyl-2-acetylsn-glycerol, and LY-294002 were obtained from Calbiochem (San Diego, CA, U.S.A.). Atropine, pilocarpine, mevastatin, mevalonic acid lactone, retinoic acid, and wortmannin were from Sigma Chemical Co. (St. Louis, MO, U.S.A.). Oxo- 
Cell culture conditions
Human SH-SY5Y neuroblastoma cells (passages 68-78) were routinely grown in 75-cm2 tissue culture flasks containing 20 ml of DMEM supplemented with 10% FCS. Cells were grown for 7-14 days at 37°C in a humidified atmosphere consisting of 90% air and 10% CO 2. Cells were retrieved from the flasks by incubation in a modified Pucks D1 solution (Honegger and Richelson, 1976) . In experiments using attached cells, the cells were subcultured into 35-mmdiameter, six-well culture plates (Becton Dickinson Labware, Lincoln Park, NJ, U.S.A.) for 2-4 days before treatment. In experiments using differentiated cells, SH-SY5Y cells were grown in the presence of 10 ,uM retinoic acid for 6 days before treatment, as described by Rosner et al. (1995) . All experiments were performed on cells that had reached confluency.
Treatment conditions and immunoprecipitations
Following removal of the plating medium, confluent 35-mm-diameter cultures of SH-SY5Y cells were washed once with 2 ml of prewarmed (37°C)treatment buffer containing 138 mM NaC1, 6 mM KC1, 1 mM MgCl2, 1 mM CaC12, 1 mM Na2HPO4, 5 mM NaHCO3, 5.5 mM glucose, and 20 mMHEPES (pH 7.4) (Offermanns et al., 1993) and allowed to equilibrate in the incubator in 1 ml of treatment buffer (with or without appropriate pretreatment) for 30 mm. Cells were then stimulated by addition of agonist to the pretreatment solution and returned to the incubator for the appropnate duration. Following agonist exposure, the treatment buffer was removed, and cells were rinsed once with 2 ml of ice-cold phosphate-buffered saline (PBS; pH 7.4). Cells were then incubated on ice and scraped into lysis buffer (200 i1per well) containing 20 mM HEPES (pH 7.4), 1% Triton X-100, 50 mM NaC1, 1 mM EGTA, 5 mM /3-glycerophosphate, 30 mM sodium pyrophosphate, 100~iMsodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 10~ig/ml aprotinin, and 10~ig/ml leupeptin (Wahl et al., 1988) . Cell debris was removed by centrifugation at 12,000 g for 5 mm at 4°C,and the protein concentration of the supernatant was determined using a commercially available protein assay kit (Pierce Chemical Co., Rockford, IL, U.S.A.). Aliquots (200 tg) of detergent-soluble cellular protein were transferred to tubes containing 1~.tgof either anti-FAK polyclonal antibody or anti-paxillin monoclonal antibody (final volume, 200 iiI) and incubated at 4°Cfor 16-20 h with continuous mixing. Protein A/G-agarose (20 /21) was added for an additional 4 h with mixing. Immune complexes were pelleted by centrifugation and washed three times with ice-cold lysis buffer. The final agarose pellet was resuspended in an equal volume of 2x sodium dodecyl sulfate (SDS) -polyacrylamide gel electrophoresis (PAGE) sample buffer, boiled for 5 mm, and electrophoresed through 10% polyacrylamide gels (Laemmli, 1970) . Proteins were transferred to polyvinylidene difluoride (PVDF) membranes (Millipore Corp., Bedford, MA, U.S.A.) and processed for immunoblot analysis. Experiments using SH-SY5Y cells maintained in suspension were performed following detachment of the cells in D 1 solution. The cells were then washed in prewarmed treatment buffer, resuspended in 5-ml aliquots of treatment buffer (with or without agonist), and incubated in a 37°Cshaking water bath for 10 mm. Samples were agitated every 5 mm to minimize cell aggregation. Following agonist exposure, 20 ml of ice-cold treatment buffer was added, and the samples were immediately placed on ice. Cells were pelleted at 4°Cby centrifugation at 1,000 g for 5 mm. Following aspiration of the supernatant, the cell pellet was homogenized on ice in 1 ml of lysis buffer by 10 strokes with a glass/glass homogenizer. Cell debris was removed by centrifugation, and immunoprecipitation of either FAK or paxillin was carried out on the supernatant as described above.
Immunoblot analysis
Nonspecific binding sites were blocked in PBS (pH 7.4) containing 0.1% Tween 20 (PBS-T) and 1% bovine serum albumin for 1 h at room temperature. Primary antibodies were diluted in blocking solution and incubated with the membranes for 1 h. Excess primary antibody was removed by washing the membranes three times in PBS-T. The blots were then incubated in peroxidase-conjugated, secondary antibody diluted in PBS-T for 1 h and subsequently washed three times in PBS-T. Immunoreactive proteins were detected by ECL. In some experiments, membranes were reprobed after stripping in 0.1 MTris-HC1 (pH 8.0), 2% SDS, and 100 mM /3-mercaptoethanol for 30 mm at 52°C.The blots were rinsed twice in PBS-T and processed as above with a different primary antibody. Autoluminograms shown are representative of two to four independent experiments. Quantitative analysis of autoluminograms was performed by computer-assisted imaging densitometry (MCID; Imaging Research, St. Catharines, Ontario, Canada).
Measurement of phosphoinositide turnover
Confluent dishes of SH-SY5Y cells were prelabeled for 48-72 h in DMEM/FCS containing 10 /2Ci/ml [ 3H]inositol. Following a 10-mm pretreatment with either wortmannin or LY-294002, cells were treated with agonist for an additional 10 mm, and the accumulation of radiolabeled inositol phosphates was determined as described previously (Thompson and Fisher, 1990) .
Phospholipid labeling from 32P,
SH-SY5Y cells plated in 35-mm-diameter wells were incubated at 37°Cin 1 ml of phosphate-free treatment buffer containing -~20/2Ci/ml 32P, for 2 h. The labeling solution was aspirated, and unincorporated 32P, was removed by washing with the same buffer. The cells were then preincubated at 37°Cfor 10 mm with vehicle (0.2% dimethyl sulfoxide), 10 jiM wortmannin, or 100 jiM LY-294002, followed by a further 10-mm incubation with either vehicle or 1 mM Oxo-M. Reactions were terminated by rapid aspiration of the treatment solution followed by addition of 0.5 ml of icecold 5% trichloroacetic acid (TCA). Cells were scraped into the TCA, transferred to glass tubes with an additional 1 ml of 5% TCA, and allowed to precipitate on ice for I h. Pellets were obtained by low-speed centrifugation at 4°C and washed once with 2 ml of ice-cold distilled water, and the final TCA pellet was resuspended in 0.5 ml of water. Lipids were extracted from the pellets with acidified chloroformmethanol as previously described (Fisher and Agranoff, 1980) . Phospholipids were then separated on oxalate-impregnated TLC plates and quantified according to a previously published method (Fisher et al., 1984) .
Other measurements
P1 3-kinase activity immunoprecipitated from lysates of SH-SY5Y cells was assayed as previously described by Lavie and Agranoff (1996) . [3HI NMS binding to intact SH-SY5Y cells was measured as previously described (Sbwiejko et al., 1996) . Tn vitro ADP-ribosylation of Rho proteins in SH-SY5Y lysates by recombinant C3 exoenzyme was performed essentially as described by Yamamoto et a!.
(1993).
Data analysis
Results shown represent the mean ±SEM values for the number (n) of independent experiments performed. Statistical differences between the means of unpaired and paired sets of data were evaluated using Student's two-tailed t tests.
RESULTS
Agonist occupancy of mAChRs increases the tyrosine phosphorylation of FAK and paxillin
In preliminary experiments, anti-phosphotyrosine immunoblots of cell lysates from Oxo-M-stimulated SH-SY5Y neuroblastoma cells demonstrated the atropine-sensitive tyrosine phosphorylation of 68-and 125-kDa proteins that comigrated with paxillin and FAK, respectively. To confirm the identity of these tyrosine-phosphorylated proteins, FAK and paxillin were immunoprecipitated from control and agonisttreated SH-SY5Y cell lysates. SH-SY5Y cells treated for 10 mm with 1 mM Oxo-M showed a 23 ±6-fold increase (n = 9) in the tyrosine phosphorylation of FAK (Fig. 1A, upper panel) , and a corresponding 6 ±1-fold increase (n = 4) in the tyrosine phosphorylatjon of paxillin ( Fig. 1 B , upper panel) . Reprobing of these blots for the precipitated proteins demonstrated equivalent immunoprecipitation efficiencies in the absence or presence of agonist ( Fig. 1A and B, lower panels). The agonist-stimulated tyrosine phosphorylation of FAK and paxillin was mediated via mAChRs, because a 10-mm pretreatment with 10 1uM atropine resulted in complete inhibition ( Fig. 1A and B, upper panels, respectively). Similar results were also observed for SH-SY5Y cells that had been differentiated in the presence of retinoic acid for 6 days before addition of agonist ( Fig. 1C and D) . Addition of a 1 mM concentration of a partial muscarinic agonist, pibocarpine, also resulted in an increased tyrosine phosphorylation of FAK but of a lesser magnitude than that observed for Oxo-M (41 ± ll%,n = 4,p <0.05).
The time course and dose-response relationships for the Oxo-M-stimulated tyrosine phosphorylation of FAK were also determined. The tyrosine phosphoryla- Confluent cultures of SH-SY5Y cells were pretreated for 10 mm in either the absence (buffer alone) or presence of 10 jiM atropine before addition of either buffer or Oxo-M (final concentration, 1 mM) for an additional 10 mm. Following treatment, cells were scraped into lysis buffer, and supernatants containing 200 jig of protein were immunoprecipitated with 1 jig of either a polyclonal antibody to FAK (A) or a monoclonal antibody to paxillin (B) as described in Materials and Methods. Immune complexes were subjected to SOS-PAGE, transferred to PVDF membranes, and immunoblotted for either phosphotyrosine (PTyr; upper panels) or the precipitated protein (lower panels). The blots in A and B are representative of fourand two independent experiments, respectively. The experiment described above was also performed in SH-SY5Y cells that had been differentiated for 6 days with 10 jiM retinoic acid before addition of Oxo-M with or without atropine, subsequent immunoprecipitation of FAK (C) and paxillin (D), and immunoblotting for PTyr.
posure to Oxo-M, was maximal at 20 mm, and returned to approximately the basal level by 120 mm in the continued presence of the agonist (Fig. 2) . Oxo-M 
Oxo-M-stimulated tyrosine phosphorylation of FAK and paxillin is independent of cell attachment
Previous reports have demonstrated that the coordinated tyrosine phosphorylation of FAK and paxillin can be mediated through interaction of cell surface integrins with ECM proteins (Burridge et a!., 1992) . Because the present experiments were conducted on SH-SY5Y cells grown on uncoated plastic, the potential for significant involvement of integrmn-ECM interactions was minimal. However, we could not exclude the possibility that SH-SY5Y cells may secrete some ECM components in response to agonist stimulation that could interact with cell surface integrins and subsequently elicit the tyrosine phosphorylation of FAK and paxillin via an integrin clustering mechanism.
Therefore, the ability of Oxo-M to stimulate the tyrosine phosphorylation of FAK and paxillin in SH-SY5Y cells maintained in suspension was assessed. Detached SH-SY5Y cells responded to the addition of Oxo-M with increases in the tyrosine phosphorylation of FAK (Fig. 3A) and paxillin ( Fig. 3B ) that were similar in magnitude to those observed for attached cells (see Fig. lA and 1B) . These results suggest that the mAChR-mediated tyrosine phosphorylation of FAK and paxillin is independent of mntegrin-ECM interactions and cell attachment.
Production of phosphoinositide-derived second messengers is not required for agonist-stimulated FAK phosphorylation
Activation of mAChRs in SH-SY5Y cells results in the formation of both sn-i ,2-diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (1P3), which subsequently activate protein kinase C (PKC) and initiate
FIG. 3.
Oxo-M induces the tyrosine phosphorylation of FAK and paxillin in SH-SY5Y cells maintained in suspension. Confluent flasks of SH-SY5Y cells were detached in D~solution, resuspended in buffer with or without Oxo-M (final concentration, 1 mM), and incubated in a shaking water bath at 37°Cfor 10 mm. Following treatment, FAK (A) or paxillin (B) immune complexes were isolated, subiected to SOS-PAGE, transferred to PVDF, and immunoblotted for phosphotyrosine as described in the legend to Fig. 1 h with 1 jiM PMA to down-regulate PKC, the basal level of tyrosine phosphorylation of FAK was increased. Under these conditions, a subsequent acute exposure to PMA did not increase the phosphorylation of FAK above this basal level (Fig. 4B) . In contrast, chronic pretreatment of cells with PMA did not impair the ability of Oxo-M to enhance the phosphorylation of FAK (Fig. 4B ). These findings suggest that DAG activation of PKC is not involved in mediating the Oxo-M-stimulated tyrosine phosphorylation of FAK. The potential role of IPrsensitive calcium release in mediating the tyrosine phosphorylation of FAK and paxillin following mAChR activation was also assessed. We have previously shown that pretreatment of SH-SY5Y cells for 30 mm with 1 jiM thapsigargin totally abolishes the TP 3-mediated increase in intracellular calcium concentration stimulated by addition of Oxo-M . In contrast, thapsigargin pretreatment did not inhibit the Oxo-M-stimulated tyrosine phosphorylation of either FAK (Fig. 4C) or paxillin (data not shown). Furthermore, no reduction in the magnitude of Oxo-M-induced phosphorylation of FAK was observed when SH-SY5Y cells were treated in a modified buffer that lacked calcium but contained 1 mM NiC12 [conditions that have previously been shown to block the plateau phase of 1P3 production and capacitative calcium entry (Wojcikiewicz et al., 1994)1. These results suggest that 1P3-sensitive calcium release and subsequent capacitative calcium entry are not involved in mediating the Oxo-M-induced tyrosine phosphorylation of FAK and paxillin.
In addition to DAG and IF3, we also investigated the potential involvement of two other phosphoinositidespecific phospholipase C (PlC) -derived second messengers [lysophosphatidic acid (LPA) and phosphatidic acid (PA)] in mediating the agonist-stimulated tyrosine phosphorylation of FAK. LPA has previously been shown to stimulate FAK phosphorylation in fibroblasts (Seufferlein and Rozengurt, 1994b) , and both of these lipids elicit an increase in the tyrosine phosphorylation of FAK when added to SH-SY5Y neuroblastoma cells (data not shown). However, neither the addition of two inhibitors of phospholipase A2 (AACOCF3 and quinacrine) nor inclusion of I -oleoyl-2-acetyl-sn-glycerol (a competitive substrate for DAG lçinase) had any significant effect on the magnitude of Oxo-M-induced tyrosine phosphorylation of FAK.
Role of the cytoskeleton and Rho in mAChRmediated FAK and paxillin tyrosine phosphorylation
Previous studies have demonstrated that the coincident tyrosine phosphorylation of FAK and paxillin mediated by multiple agonists is dependent on the integrity of the cellular actin microfilament network (Seufferlein and Rozengurt, 1994a,b; Flinn and Ridley, 1996) . In SH-SY5Y cells, a 30-mm pretreatment with 1 jiM cytochalasin D (a compound that selectively disrupts actin microfilaments) completely abolished the Oxo-M-stimulated tyrosine phosphorylation of both FAK (Fig. SA) and paxillin (Fig. SB) . Cytochalasin D was also effective at blocking the agoniststimulated phosphorylation of FAK in SH-SY5Y cells maintained in suspension (data not shown). In con- trast, cytochalasin D pretreatment had no effect either on the mAChR-mediated activation of ERK1 and ERK2 (Fig. 5C ) or on agonist-induced mAChR sequestration monitored by a loss of [ 3HJNMS binding sites (an -~40%loss in control cells vs. a 45% loss in cytochalasin D-pretreated cells).
The agonist-stimulated tyrosine phosphorylation of FAK and paxillin was also significantly attenuated when SH-SY5Y cells were preincubated for 24 h with 10 jiM mevastatin. Mevastatin is an inhibitor of hydroxymethylglutaryl-CoA reductase, which has been shown to destabilize actin microfilaments via blockade of synthesis of mevalonate, a precursor required for the isoprenylation of low-molecular-weight G proteins involved in cytoskeletal regulation (Bokoch and Prossnitz, 1992; Fenton et a!., 1992; Bifulco et a!., 1993) . Mevastatin pretreatment significantly inhibited the Oxo-M-stimulated tyrosine phosphorylation of both FAK (Fig. 6A) and paxillin (Fig. 6B) . Mevastatin also induced marked morphological changes characterized primarily by cellular rounding. All of these effects were blocked to a significant degree if cells were preincubated with mevastatin in the presence of 1 mM mevalonate (Fig. 6) . Pretreatment with mevalonate alone did not alter the basal or agonist-stimulated phosphorylation of FAK or paxillin (data not shown).
Although recent findings have demonstrated that the low-molecular-weight G protein Rho may play a role in mediation of the tyrosine phosphorylation of FAK in fibroblasts (Rankin et al., 1994; Flinn and Ridley, 1996) , no such evidence was obtained for SH-SY5Y cells. Thus, a 48-h preincubation of SH-SY5Y cells with 12.5 jig/rn! C3 exoenzyrne (a protein isolated from Clostridium botulinum that selectively ADP-ribosylates and inactivates Rho proteins) had no significant effect on the Oxo-M-stimulated tyrosine phosphorylation of FAK (Fig. 7) . Subsequent in vitro measurements of ADP-ribosylation of Rho proteins in lysates from C3 exoenzyme-pretreated SH-SY5Y cells revealed an~=35% decrease in 32P incorporation compared with vehicle-pretreated cells.
Wortmannin and LY-294002 attenuate the agonist-stimulated tyrosine phosphorylation of FAK and paxillin and selectively decrease 32P labeling of PI(4)P
Phosphoinositides may play a key role in the maintenance of the cytoskeleton (Lassing and Lmndberg, 1985; Yu et a!., 1990; Fukami et a!., 1992; Hartwig et al., 1995) . Given that an intact cytoskeleton is a prerequisite for the agonist-stimulated tyrosine phosphorylation of FAK and paxillin, a direct role for the inositol lipids in these signaling events was investigated by examining the effects of two structurally unrelated inhibitors of phosphoinositide synthesis. Inclusion of low concentrations of either wortmannin ( 100 nM) or LY-294002 ( 10 jiM), conditions under which P1 3-kinase activity is markedly inhibited in SH-SY5Y cells (>95% inhibition with 100 nM jig/mi C3 Exo in DMEM containing 10% FCS before a 10-mm exposure to 1 mM Oxo-M. Following agonist treatment, FAK immune complexes were isolated, subjected to SOS-PAGE, transferred to PVDF, and immunoblotted for phosphotyrosine as described in the legend to Fig. 1 . The blot shown is representative of three independent experiments. wortmannin and >60% inhibition with 10 jiM LY-294002), had no effect on the agonist-stimulated tyrosine phosphorylation of either FAK or paxillin. However, pretreatment of SH-SY5Y cells with higher concentrations of either inhibitor, conditions under which PT 4-kinase activity is reported to be inhibited Downing et al., 1996; Meyers and Cantley, 1997) , resulted in complete inhibition of the tyrosine phosphorylation of FAK (IC 50 values for wortrnannin and LY-294002, 478 nM and 23 jiM, respectively; Figs. 8A and B and 9A and B) . In parallel experiments, both wortmannin and LY-294002 also inhibited the tyrosine phosphorylation of paxillin with dose-inhibition relationships similar to those observed for FAK (Figs. 8C and 9C) .
Consistent with the ability of these agents to inhibit P1 4-kinase activity, pretreatment of SH-SY5Y cells with either 10 jiM wortmannin or 100 jiM LY-294002 resulted in a selective decrease in the basal 32P labeling of PI(4)P by 79 ±2 and 60 ±4%, respectively (n = 3; Fig. 10 ). Neither inhibitor had any significant effect on the basal labeling of PA, P1, or PT 4,5-bisphosphate [P1(4,5) P 2 1. Following addition of Oxo-M to 32P-prelabeled cells, there was a marked increase in [32PI PA and [32P11 P1 labeling, whereas the radioactivity incorporated into PI(4)P and PI(4,5)P 2 was de- creased (Fig. 10) . Preincubation of 32P-labeled cells with either wortmannin or LY-294002 substantially reduced the agonist-mediated increases in the labeling of PA and PT and resulted in further decreases in the labeling of PI(4)P and PI(4,5)P 2 (Fig. 10) . As a consequence of their ability to block the resynthesis of PI (4) 
DISCUSSION
In this study, we demonstrate that agonist occupancy of m3 mAChRs in SH-SY5Y neuroblastoma cells results in an increased tyrosine phosphorylation of FAK and paxillin, two proteins that have recently been implicated in a signal transduction pathway linked to neurite outgrowth (Bianchi et a!., 1995; Maroney et a!., 1995; Leventhal and Feldman, 1996; Leventhal et al., 1997) . Although two previous studies have reported that stimulation of mAChRs transfected into either fibroblasts (Gutkind and Robbins, 1992) or Chinese hamster ovary cells (Savage et a!., 1995) can elicit an increase in the tyrosine phosphorylation of FAK, the present study is the first demonstration of such for an endogenous mAChR in a neural cell line. In addition, the mAChR-mediated tyrosine phosphorylation of FAK and paxillin was observed in both undifferentiated and retinoic acid-differentiated SH-SY5Y cells. The mAChR-mediated tyrosine phosphorylation of FAK and paxillin in SH-SY5Y cells is independent of integrin interactions with the ECM, as phosphorylation of both proteins could be readily demonstrated when cells were maintained in suspension (Fig. 3) . This observation ms in contrast to previous reports demonstrating that, following activation of integrin receptors, detachment of cells from the ECM results in the rapid dephosphorylation of FAK and paxillin (Kornberg et al., 1992; Leventhal and Feldman, 1996) . However, our results are in agreement with a recent study in which an enhanced phosphorylation of FAK was observed in response to addition of either LPA or active Rho protein to suspensions of (scrape-loaded) Swiss 3T3 fibroblasts (Flinn and Ridley, 1996) . Thus, it appears that cell attachment is not invariably a prerequisite for the increased tyrosine phosphorylation of FAK and paxillin and that the signaling events that initiate this phosphorylation cascade following mAChR activation in SH-SY5Y cells can occur in an environment devoid of focal contacts with the ECM. There is some uncertainty regarding the role that phosphoinositide-derived second messengers, e.g., 1P3 and DAG, may play in mediating the enhanced tyrosine phosphorylation of FAK following agonist occupancy of receptors coupled to PlC activation. For example, whereas evidence suggesting the involvement of either PKC or Ca 2~has been obtained (Leeb-Lundberg et al., 1994; Savage et al., 1995) , the results from other studies are inconsistent with these observations (Sinnet-Smith et a!., 1993; Seuffer!ein and Rozengurt, 1994b) . Our results indicate that, in SH-SY5Y cells, the production of phosphoinositide-derived second messengers is not a prerequisite for the enhanced tyrosine phosphorylation of FAK elicited by mAChR stimulation. The evidence for this conclusion is threefold. First, neither the inhibition of PKC by Ro 31-8220 nor its depletion from cells by chronic PMA pretreatment decreased the extent of tyrosine phosphorylation of FAK in response to mAChR activation. Second, neither depletion of intracellular Ca2~stores with thapsigargin nor blockade of Ca2~entry with Ni 2±attenuated the phosphorylation of FAK. Third, no evidence was obtained for the involvement of other putative downstream messenger molecules such as PA or LPA, given that inhibitors of DAG kinase and phospholipase A 2 had no effect on the agonist-stimulated phosphorylation of FAK. The absence of a requirement for PKC activation in the mAChR-mediated tyrosine phosphorylation of FAK is in contrast to the previously demonstrated role for PKC in the stimulation of the mitogenactivated protein kinase (MAPK) pathway elicited by activation of the same receptors in these cells (Offermanns et al., 1993) . This observation is of significance because the tyrosine phosphorylation of FAK has been linked to activation of the Ras /MAPK cascade via the association of FAK with the adapter protein GRB-2 (Schlaepfer eta!., 1994) . However, in SH-SY5Y cells, the mAChR-mediated activation of FAK and that of MAPK appear to be parallel, but independent, events.
A characteristic feature of the tyrosine phosphorylation of FAK elicited in responseto addition of a diverse range of stimuli is its susceptibility to addition of cytochalasin D with the attendant disruption of the actin cytoskeleton. The increases in the tyrosine phosphorylation of FAK and paxillin resulting from mAChR activation in SH-SY5Y cells were similarly prevented by inclusion of cytochalasin D (Fig. 5) . Cytochalasin D sensitivity was also observed for mAChR-mediated increases in the tyrosine phosphorylation of FAK e!icited in SH-SY5Y cells maintained in suspension (data not shown). In contrast, other consequences of mAChR activation in these cells, such as receptor internalization and MAPK activation, were unaffected by cytochalasin D. The conclusion that an intact actin cytoskeleton is required for FAK phosphorylation was further substantiated by the observation that pretreat-ment of the cells with mevastatin, an agent known to destabilize actin microfilaments, also attenuated the agonist-stimulated tyrosine phosphorylation of FAK and paxillin. The inhibitory effects of mevastatin could largely be prevented by inclusion of mevalonate, a precursor molecule required for the isoprenylation of various proteins, including some low-molecularweight G proteins implicated in the regulation of the cytoskeleton. In this context, recent studies indicate that in fibroblasts, the low-molecular-weight G protein p2lRho may play a pivotal role in mediating the tyrosine phosphorylation of FAK and paxillin (Rankin et al., 1994; Flinn and Ridley, 1996) . This may not be the case for the mAChR-mediated tyrosine phosphory-!ation of FAK in SH-SY5Y neuroblastoma cells because pretreatment with C3 exoenzyme failed to prevent the agonist-induced increase in the tyrosine phosphorylation of FAK. However, as only a partial ADPribosylation of Rho proteins in SH-SY5Y cells was observed, any such conclusion must remain tentative. Recently it has been shown that mAChR-mediated actin stress fiber formation in transfected Chinese hamster ovary cells is also insensitive to C3 exoenzyme . Taken collectively, these results suggest that if a low-molecular-weight G protein is involved in the mAChR-mediated alterations of the cytoskeleton and signaling events that lead to the tyrosine phosphorylation of FAK, it may not invariably be Rho.
The actin cytoskeleton is known to be markedly influenced by phosphoinositides. For example, these lipids modulate the functions of several actin binding proteins (Lassing and Lindberg, 1985; Yu et a!., 1990; Fukami et a!., 1992) and can induce actin filament uncapping, thereby facilitating actin polymerization (Hartwig et al., 1995) . A major finding to emanate from the present study is that the synthesis of polyphosphoinositides, specifically that of P1(4) F, is required for the increased tyrosine phosphorylation of FAK and paxillin in response to mAChR activation. Pretreatment of SH-SY5Y cells with concentrations of either wortmannin or LY-294002 that inhibit the synthesis of P1(4) P resulted in a marked attenuation of the phosphorylation of FAK and paxillin (see Figs. 8 and 9) . In contrast, no inhibition of phosphorylation was observed at concentrations of these inhibitors ( 100 nM for wortmannin and 10 jiM for LY-294002) that are more specific for inhibition of PT 3-kinase (Yano et al., 1995) . In this context, it should be noted that inclusion of either 30 nM wortmannin or 10 jiM LY-294002 has been reported to inhibit the enhanced tyrosine phosphorylation of FAK in plateletderived growth factor-stimulated fibroblasts by 65-100%, a result consistent with the involvement of PT 3-kinase (Rankin et al., 1996) . However, in the same study, these inhibitor concentrations were without effect on the tyrosine phosphorylation of FAK induced by activation of bombesin receptors (which, like mAChRs, couple to PlC via Gq). Although both wortmannin and LY-294002 have also been demonstrated to inhibit activity of myosin light chain kinase (MLCK) (Yano et al., 1995) , a key enzyme involved in the regulation of actin/myosin interactions and cell contractility (see Burridge and Chrzanowska-Wodnicka, 1996) , a role for this enzyme in the mAChRmediated tyrosine phosphorylation of FAK and paxillin appears unlikely for three reasons. First, although MLCK is a Ca 2~-dependentenzyme, there is no such Ca2~requirement for the phosphorylation of FAK and paxillin (see Fig. 4C ). Second, pretreatment of SH-SY5Y cells with 10 jiM ML-7, a known inhibitor of MLCK, was without effect on the phosphorylation of FAK (data not shown). Third, whereas pretreatment of SH-SY5Y cells with 100 jiM LY-294002 resulted in a >95% inhibition of the tyrosine phosphorylation of FAK and paxillin, only a small inhibitory effect on MLCK is observed at this concentration (Yano et al., 1995 ). An additional possibility, i.e., that wortmannin directly inhibits the autokinase activity of FAK, also appears unlikely given that other tyrosine kinases, e.g., Src or MEK, are not inhibited by wortmannin (Brunn et al., 1996) . In agreement with their reported ability to inhibit PT 4-kinase activity Downing et a!., 1996; Meyers and Cantley, 1997) , addition of either wortmannin or LY-294002 to SH-SY5Y cells resulted in a selective inhibition of P1(4) P synthesis, as demonstrated by a decreased 32P labeling (Fig. 10) . In the presence of Oxo-M, which when added alone reduces PI(4)P and PT(4,5)P 2 labeling, the inclusion of either inhibitor resulted in a further reduction in polyphosphoinositide labeling. As anticipated, inhibition of polyphosphomnositide synthesis by wortmannin or LY-294002 resulted in a marked reduction in the extent of mAChR-stimulated inositol lipid hydrolysis, as monitored by the release of radiolabeled inositol phosphates. From dose-inhibition studies, the latter parameter was found to be highly correlated with the extent of inhibition of the tyrosine phosphorylation qf FAK for both wortmannin (r = 0.995, p < 0.001) and LY-294002 (r = 0.976, p <0.01). Taken collectively, these results suggest that wortmannin and LY-294002 deplete the cellular content of phosphoinositides. A consequence of this may be that the normal maintenance of the actin cytoskeleton by these lipids is compromised, thereby depriving FAK of the required environment in which it can autophosphorylate and become fully activated.
In summary, the present results indicate that on agonist occupancy of mAChRs in SH-SY5Y cells, there is a marked increase in the tyrosine phosphorylation of FAK and paxillin. Increases in phosphorylation occur independently of the production of phosphoinositidederived second messengers but require the continuous synthesis of inositol lipids. The latter may reflect a role for these lipids in the maintenance of an intact actin cytoskeleton, which is a prerequisite for the increased tyrosine phosphorylation of FAK and paxillin.
